229 research outputs found
Quantum Mechanics of Semiconductor Quantum Dots and Rings
We consider the several phenomena which are taking place in Quantum Dots (QD)
and Quantum Rings (QR): The connection of the Quantum Chaos (QC) with the
reflection symmetry of the QD, Disappearance of the QC in the tunnel coupled
chaotic QD, electron localization and transition between Double Concentric QR
in the transverse magnetic field, transition of electron from QR to the QD
located in the center of QR. Basis of this consideration is the effective
Schr\"odinger equation for the corresponding systems.Comment: 32 pages, 26 figures; This paper is the basis of two talks of Sergei
Matinyan presented at the workshop "Low Dimension Systems & Gauge principle"
(Yerevan, Tbilisi, 2011
A Pair Polarimeter for Linearly Polarized High Energy Photons
A high quality beam of linearly polarized photons of several GeV will become
available with the coherent bremsstrahlung technique at JLab. We have developed
a polarimeter which requires about two meters of the beam line, has an
analyzing power of 20% and an efficiency of 0.02%. The layout and first results
of a polarimeter test on the laser back-scattering photon beam at SPring-8/LEPS
are presented
Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor
BACKGROUND: Tumoural interstitial hypertension, possibly modulated by platelet-derived and vascular endothelial growth factor receptors (PDGFR and VEGFR), may mediate resistance to chemotherapy. METHODS: Forty-eight patients with advanced solid tumours received oral PDGFR inhibitor CP-868,596 (60-100 mg twice daily (BID)) and docetaxel (75-100 mg m⁻²), or CP-868,596 (60 mg BID), docetaxel (75 mg m⁻²), and VEGFR inhibitor axitinib (5 mg BID). RESULTS: The CP-868,596/docetaxel was escalated as above. The CP-868,596/docetaxel/axitinib was not dose escalated because of increased incidence of mucositis-like adverse events (AEs) with concurrent neutropenia relative to that expected for docetaxel. All tested regimens were tolerable, including 100 mg BID CP-868,596 (recommended phase II dose) plus 100 mg m⁻² docetaxel (maximum approved dose). Most treatment-emergent AEs were mild-moderate and reversible, commonly including nausea, diarrhoea, vomiting, constipation, fatigue, and anaemia (CP-868,596/docetaxel), and hypertension, lethargy, diarrhoea, and fatigue (CP-868,596/docetaxel/axitnib). Pharmacokinetics were unaffected by co-administration. Twenty-one patients achieved stable disease, including all seven evaluable on CP-868,596/docetaxel/axitinib. All nine CP-868,596/docetaxel/axitinib patients received therapy for a median of six (range, 3-16) cycles. CONCLUSIONS: The CP-868,596/docetaxel was well tolerated, but increased efficacy was not observed. Addition of axitinib delivered greater benefits than expected in the number of patients achieving prolonged stable disease with a moderate increase in AEs
- …